Sign In
Buy OPRX
$6.05
-0.220 (-3.51%)
At Close: Jul 31, 2026
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
07:30am, Monday, 10'th Mar 2025
Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team Silvestro has a demonstrated record of accelerating revenue growth, ex
OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET
07:30am, Thursday, 27'th Feb 2025
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and
OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
08:45am, Monday, 23'rd Dec 2024
WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and e
OptimizeRx initiated with an Equal Weight at Stephens
04:25pm, Thursday, 19'th Dec 2024
Stephens initiated coverage of OptimizeRx with an Equal Weight rating and $5.50 price target. The firm says the company's "evolving" direct-to-consumer business model toward self-service may create he
OptimizeRx to Participate in Upcoming Investor Conferences
07:30am, Monday, 18'th Nov 2024
WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach an
OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript
10:58pm, Wednesday, 13'th Nov 2024
OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2024 Results Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financi
OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates
06:35pm, Wednesday, 13'th Nov 2024
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.09 per share a year ago.
OptimizeRx (OPRX) Surges 19.8%: Is This an Indication of Further Gains?
10:16am, Thursday, 07'th Nov 2024
OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET
07:30am, Thursday, 31'st Oct 2024
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and
OptimizeRx (OPRX) Moves 5.4% Higher: Will This Strength Last?
05:26am, Thursday, 03'rd Oct 2024
OptimizeRx (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach an
OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences
12:00pm, Monday, 09'th Sep 2024
The availability of Micro-Neighborhood ® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround
10:37am, Wednesday, 04'th Sep 2024
The heavy selling pressure might have exhausted for OptimizeRx (OPRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
OptimizeRx Corp. (OPRX) Tops Q2 Earnings Estimates
07:26pm, Thursday, 08'th Aug 2024
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.01 per share a year ago.
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Should You Buy?
11:05am, Thursday, 01'st Aug 2024
OptimizeRx (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
